SW
CCCC icon

Simplicity Wealth’s C4 Therapeutics CCCC Stock Holding History

Simplicity Wealth’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.9K Sell
10,045
-156
-2% -$534 ﹤0.01% 1005
2026
Q1 		$26.8K Sell
10,201
-1
-0% -$2 ﹤0.01% 741
2025
Q4 		$19.5K Sell
10,202
-11
-0.1% -$26 ﹤0.01% 697
2025
Q3 		$22.7K Buy
+10,213
New +$24.5K ﹤0.01% 705

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Simplicity Wealth's CCCC Position: Q2 2026 in Review

Simplicity Wealth reduced its C4 Therapeutics (CCCC) stake by 1.5% in Q2 2026, selling an estimated $534 and leaving 10,045 shares worth $46.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1005.

Simplicity Wealth first reported a position in CCCC in Q3 2025 and has held it in 4 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Simplicity Wealth held 10,045 shares of C4 Therapeutics worth $46.9K as of Q2 2026.
  • Simplicity Wealth sold 156 C4 Therapeutics shares in Q2 2026, an estimated $534.
  • C4 Therapeutics made up ﹤0.01% of Simplicity Wealth's portfolio in Q2 2026, its #1005 holding.
  • Simplicity Wealth first reported a position in C4 Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Simplicity Wealth's 13F filing for Q2 2026, filed 6 Aug 2026.